Prognostic significance of serum cystatin C in acute ischemic stroke patients according to lipid component levels

Serum cystatin C (CysC) is associated with the risk of ischemic stroke and may predict cardiovascular events and death after ischemic stroke onset. However, the association between serum CysC and functional outcome in ischemic stroke patients remains unclear, and whether lipid component level influe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 2018-07, Vol.274, p.146-151
Hauptverfasser: Zhu, Zhengbao, Zhong, Chongke, Xu, Tian, Wang, Aili, Peng, Yanbo, Xu, Tan, Peng, Hao, Chen, Chung-Shiuan, Wang, Jinchao, Li, Qunwei, Geng, Deqin, Sun, Yingxian, Li, Yongqiu, Zhang, Yonghong, He, Jiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Serum cystatin C (CysC) is associated with the risk of ischemic stroke and may predict cardiovascular events and death after ischemic stroke onset. However, the association between serum CysC and functional outcome in ischemic stroke patients remains unclear, and whether lipid component level influences the relationship between them has not been studied. A total of 3348 ischemic patients from China Antihypertensive Trial in Acute Ischemic Stroke were included in the study. Serum CysC was used to calculate estimated glomerular filtration rate (eGFRCysC) at baseline. The primary outcome was poor functional outcome (modified Rankin Scale score ≥3) at one year after ischemic stroke. Secondary outcomes were death, stroke recurrence, vascular events and combination of the aforementioned outcomes. The association between eGFRCysC and primary outcome was appreciably modified by low-density lipoprotein cholesterol (LDL-C) (pinteraction = 0.048). Low eGFRCysC was associated with primary outcome only in ischemic stroke patients with LDL-C ≥4.14 mmol/l rather than all patients. The multivariable adjusted odds ratio (95% confidence interval) of poor functional outcome associated with low eGFRCysC was 3.94 (1.04–14.98) and a positive linear dose-response relationship between them was observed among patients with LDL-C ≥4.14 mmol/l (p for linearity = 0.021). Subgroup analyses further confirmed these associations. There was no association between eGFR based on serum creatinine and poor functional outcome of stroke. Low eGFRCysC may be an independent predictor for 1-year poor functional outcome in ischemic stroke patients with LDL-C ≥4.14 mmol/l. Further studies are needed to replicate our findings and to clarify the potential mechanisms. •The first study to explore the association between cystatin C and functional outcome of stroke stratified by lipid.•This is a large-sample multicenter study with high statistical power in different lipid components subgroups.•Low eGFRCysC may be an predictor for 1-year functional outcome in ischemic stroke patients with LDL-C ≥4.14 mmol/l.
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2018.05.015